Comparison of Claims Between U.S. Patent Nos. 6,774,122; 7,456,160; 8,329,680; 8,466,139				
	6,774,122 *Independent Claims 1 and 5*	**7,456,160** *Independent Claims 1 and 2*	**8,329,680** *Independent Claims 1 and 9*	**8,466,139** *Independent Claim 1 and 11*
Treatment	A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract			
Injection Type	Intramuscularly to a human			
Fulvestrant	>45 $mgml^{-1}$ of fulvestrant *(claim 5)*	>45 $mgml^{-1}$ of fulvestrant *(claim 2)*	about 50 $mgml^{-1}$ fulvestrant	about 50 $mgml^{-1}$ fulvestrant
Ethanol	10% w/v	10–30% w/v combined	about 10% w/v	17–23% w/v combined
Benzyl Alcohol	10% w/v		about 10% w/v	
Benzyl Benzoate	15% w/v	10–25% w/v	about 15% w/v	12–18% w/v
Castor Oil	a sufficient amount[1]			
PK Result	whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 $ngml^{-1}$ is attained for at least 2 weeks after injection *(claim 1 only)*	whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 $ngml^{-1}$ is attained for at least 2 weeks after injection *(claim 1 only)*	wherein the method achieves a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 $ngml^{-1}$ for at least four weeks	wherein the method achieves a blood plasma fulvestrant concentration of at least 2.5 $ngml^{-1}$ for at least two weeks

[1] Omitted from U.S. Patent No. 8,329,680, claim 9.

Dependent Claims				
	6,774,122 ***Independent Claims 1 and 5***	**7,456,160** ***Independent Claims 1 and 2***	**8,329,680** ***Independent Claims 1 and 9***	**8,466,139** ***Independent Claim 1 and 11***
Breast Cancer	**2, 9**	**12**	**3, 6, 11, 14**	**5, 10, 15, 20**
PK Result (Raising Blood Plasma Conc. Levels or Extending Time Periods)	**3–4** *Claim 3: ≥2.5 $ngml^{-1}$ for ≥4 weeks* *Claim 4: ≥2.5 $ngml^{-1}$ for ≥2–5 wks.*	**5–9** *Claim 5: ≥2.5 $ngml^{-1}$ for ≥3 weeks* *Claim 6: ≥2.5 $ngml^{-1}$ for ≥4 weeks* *Claim 7: ≥3 $ngml^{-1}$ for ≥2 weeks* *Claim 8: ≥8.5 $ngml^{-1}$ for ≥2 weeks* *Claim 9: ≥8.5 $ngml^{-1}$ for ≥4 weeks*	**2, 10** *Claim 2: ≥8.5 $ngml^{-1}$ for ≥4 wks.* *Claim 10:≥2.5 $ngml^{-1}$ for ≥4 wks.*	**4, 6, 10, 14, 16, 20** *Claims 4, 14: ≥8.5 $ngml^{-1}$ for ≥2 weeks* *Claims 6, 10, 16, 20: ≥2.5 $ngml^{-1}$ for ≥4 weeks*
Divided Dose			**17–20**	**9, 19**
Once Monthly			**5, 8, 13, 16**	**8, 18**
Limiting Injection Volume	**6–8** *Claims 6, 7: ≤6 ml* *Claim 8: 5–5.25 ml*	**10–11** *Claims 10, 11: ≤6 ml*	**4, 7, 12, 15** *Claims 4, 7, 12, 15: 5 ml*	**7, 17** *Claims 7, 17: 5 ml*
Limiting Conc. & Dose	**6–8** *Claims 5,6: ≥45 $mgml^{-1}$* *Claim 7: ≥250 mg* *Claim 8: 250mg*	**10–11** *Claim 2,10: ≥45 $mgml^{-1}$* *Claim 11: ≥250 mg*		
Further Narrowing Excipient %		**3–4** *Claim 3:* *15–25% w/v ethanol & benzyl alcohol,* *12–20% w/v benzyl benzoate* *Claim 4:* *8.5–11.5% w/v ethanol,* *8.5–11.5% w/v benzyl alcohol,* *12–18% w/v benzyl benzoate*		**2–3, 12–13** *Claims 2, 12:* *19–21% w/v ethanol & benzyl alcohol,* *14–16% w/v benzyl benzoate* *Claims 3, 13:* *about 10% w/v ethanol,* *about 10% w/v benzyl alcohol,* *about 15% w/v benzyl benzoate*